Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Current Deferred Revenue (2024 - 2025)

Fennec Pharmaceuticals filings provide 2 years of Current Deferred Revenue readings, the most recent being $248000.0 for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue changed 0.0% to $248000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $248000.0, a 0.0% change, with the full-year FY2025 number at $248000.0, changed 0.0% from a year prior.
  • Current Deferred Revenue hit $248000.0 in Q4 2025 for Fennec Pharmaceuticals, roughly flat from $248000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $252000.0 in Q1 2024 to a low of $248000.0 in Q3 2024.